Literature DB >> 10479605

Medical care expenditures for diabetes, its chronic complications, and its comorbidities.

T A Hodgson1, A J Cohen.   

Abstract

BACKGROUND: Medical expenditures for diabetes are estimated, including expenditures for chronic complications of diabetes, unrelated conditions for which diabetics are at higher risk, and various comorbidities that raise the cost of medical care.
METHODS: A variety of national data sources are used to disaggregate the Health Care Financing Administration's national health expenditures in 1995 by sex, age, and diagnosis. Expenditures for chronic complications and other unrelated conditions for which diabetics have higher rates of utilization are determined by analysis of attributable risks. Additional expenditures generated by extra hospital inpatient days and higher charges for nursing home and home health care for comorbidities are estimated by regression analyses. Sensitivity analysis is used to calculate a range of estimated expenditures.
RESULTS: Total expenditures attributed to diabetes are $47.9 billion in 1995, including $18.8 billion for first listed diabetes, $18.7 billion for chronic complications, $8.5 billion for unrelated conditions, and $1.9 billion for comorbidities. The range of total expenditures is $34.3 to $63.7 billion.
CONCLUSIONS: Comprehensive accounting of expenditures more accurately assesses the economic burden of diabetes and potential savings from prevention, especially of chronic complications. This analysis is illustrative for other chronic illnesses.

Entities:  

Mesh:

Year:  1999        PMID: 10479605     DOI: 10.1006/pmed.1999.0534

Source DB:  PubMed          Journal:  Prev Med        ISSN: 0091-7435            Impact factor:   4.018


  15 in total

1.  Disease burden profiles: an emerging tool for managing managed care.

Authors:  Yang Zhao; Arlene S Ash; Randall P Ellis; James P Slaughter
Journal:  Health Care Manag Sci       Date:  2002-08

Review 2.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

3.  Diabetes and the hospitalized patient : A cluster analytic framework for characterizing the role of sex, race and comorbidity from 2006 to 2011.

Authors:  Nisha Nataraj; Julie Simmons Ivy; Fay Cobb Payton; Joseph Norman
Journal:  Health Care Manag Sci       Date:  2017-07-22

Review 4.  Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus.

Authors:  Christopher J Dunn; Greg L Plosker
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

5.  US Spending on Personal Health Care and Public Health, 1996-2013.

Authors:  Joseph L Dieleman; Ranju Baral; Maxwell Birger; Anthony L Bui; Anne Bulchis; Abigail Chapin; Hannah Hamavid; Cody Horst; Elizabeth K Johnson; Jonathan Joseph; Rouselle Lavado; Liya Lomsadze; Alex Reynolds; Ellen Squires; Madeline Campbell; Brendan DeCenso; Daniel Dicker; Abraham D Flaxman; Rose Gabert; Tina Highfill; Mohsen Naghavi; Noelle Nightingale; Tara Templin; Martin I Tobias; Theo Vos; Christopher J L Murray
Journal:  JAMA       Date:  2016-12-27       Impact factor: 56.272

6.  Spending on Children's Personal Health Care in the United States, 1996-2013.

Authors:  Anthony L Bui; Joseph L Dieleman; Hannah Hamavid; Maxwell Birger; Abigail Chapin; Herbert C Duber; Cody Horst; Alex Reynolds; Ellen Squires; Paul J Chung; Christopher J L Murray
Journal:  JAMA Pediatr       Date:  2017-02-01       Impact factor: 16.193

7.  Examining the economic costs related to lifestyle and pharmacological interventions in youth with Type 2 diabetes.

Authors:  Thomas Songer; Judith Glazner; Laura P Coombs; Leona Cuttler; Mary Daniel; Silvia Estrada; Georgeanna Klingensmith; Andrea Kriska; Lori Laffel; Ping Zhang
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2006-06-01       Impact factor: 2.217

Review 8.  Challenges in building disease-based national health accounts.

Authors:  Allison B Rosen; David M Cutler
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

Review 9.  Cost-of-illness studies in diabetes mellitus.

Authors:  Lorraine Ettaro; Thomas J Songer; Ping Zhang; Michael M Engelgau
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

10.  What part of the total care consumed by type 2 diabetes patients is directly related to diabetes? Implications for disease management programs.

Authors:  Christel E van Dijk; Robert A Verheij; Ilse C S Swinkels; Mieke Rijken; François G Schellevis; Peter P Groenewegen; Dinny H de Bakker
Journal:  Int J Integr Care       Date:  2011-12-14       Impact factor: 5.120

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.